BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 37022517)

  • 1. A pan-cancer analysis of RNASEH1, a potential regulator of the tumor microenvironment.
    Yi C; Yang J; Zhang T; Xie S; Li W; Qin L; Chen D
    Clin Transl Oncol; 2023 Aug; 25(8):2569-2586. PubMed ID: 37022517
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Pan-Cancer Analysis of CD161, a Potential New Immune Checkpoint.
    Zhou X; Du J; Liu C; Zeng H; Chen Y; Liu L; Wu D
    Front Immunol; 2021; 12():688215. PubMed ID: 34305920
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pan-cancer analysis of the oncogenic role of ribonucleotide reductase subunit M2 in human tumors.
    Li Y; Fu W; Geng Z; Song Y; Yang X; He T; Wu J; Wang B
    PeerJ; 2022; 10():e14432. PubMed ID: 36518297
    [TBL] [Abstract][Full Text] [Related]  

  • 4. POC1A, prognostic biomarker of immunosuppressive microenvironment in cancer.
    Zhao Q; Gao S; Chen X; Zhu X
    Aging (Albany NY); 2022 Jun; 14(12):5195-5210. PubMed ID: 35748773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pan-cancer analysis reveals correlation between RAB3B expression and tumor heterogeneity, immune microenvironment, and prognosis in multiple cancers.
    Liu XS; Chen YL; Chen YX; Wu RM; Tan F; Wang YL; Liu ZY; Gao Y; Pei ZJ
    Sci Rep; 2024 Apr; 14(1):9881. PubMed ID: 38688977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An integrative analysis revealing POLD2 as a tumor suppressive immune protein and prognostic biomarker in pan-cancer.
    Cong F; Long J; Liu J; Deng Z; Yan B; Liang C; Huang X; Liu J; Tang W
    Front Genet; 2022; 13():877468. PubMed ID: 36081989
    [No Abstract]   [Full Text] [Related]  

  • 7. FUCA2 Is a Prognostic Biomarker and Correlated With an Immunosuppressive Microenvironment in Pan-Cancer.
    Zhong A; Chen T; Xing Y; Pan X; Shi M
    Front Immunol; 2021; 12():758648. PubMed ID: 34745134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calreticulin, a potential coregulator of immune checkpoints and biomarker associated with tumor microenvironment and clinical prognostic significance in breast invasive carcinoma.
    Lin J; Chen Y; Zhang Z; Qi F; Zhang M
    Environ Toxicol; 2024 May; 39(5):2717-2731. PubMed ID: 38247288
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic and immunological role of SERPINH1 in pan-cancer.
    Zhong H; Wang Z; Wei X; Liu Y; Huang X; Mo X; Tang W
    Front Genet; 2022; 13():900495. PubMed ID: 36105106
    [No Abstract]   [Full Text] [Related]  

  • 10. Pan-Cancer Analysis of PDIA3: Identifying It as a Potential Biomarker for Tumor Prognosis and Immunotherapy.
    Zhang J; Wang K; Hainisayimu T; Li H
    Oxid Med Cell Longev; 2022; 2022():9614819. PubMed ID: 36046686
    [TBL] [Abstract][Full Text] [Related]  

  • 11. TRPV4 is a Prognostic Biomarker that Correlates with the Immunosuppressive Microenvironment and Chemoresistance of Anti-Cancer Drugs.
    Wang K; Feng X; Zheng L; Chai Z; Yu J; You X; Li X; Cheng X
    Front Mol Biosci; 2021; 8():690500. PubMed ID: 34262942
    [No Abstract]   [Full Text] [Related]  

  • 12. Comprehensive Pan-Cancer Genomic Analysis Reveals PHF19 as a Carcinogenic Indicator Related to Immune Infiltration and Prognosis of Hepatocellular Carcinoma.
    Zhu ZY; Tang N; Wang MF; Zhou JC; Wang JL; Ren HZ; Shi XL
    Front Immunol; 2021; 12():781087. PubMed ID: 35069553
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Significance and Immunological Role of FBXO5 in Human Cancers: A Systematic Pan-Cancer Analysis.
    Liu P; Wang X; Pan L; Han B; He Z
    Front Immunol; 2022; 13():901784. PubMed ID: 35720327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. IMPDH1, a prognostic biomarker and immunotherapy target that correlates with tumor immune microenvironment in pan-cancer and hepatocellular carcinoma.
    Liu C; Zhang W; Zhou X; Liu L
    Front Immunol; 2022; 13():983490. PubMed ID: 36618420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 16. SHCBP1 Is a Prognostic Biomarker Related to the Tumour Immune Microenvironment in Pan-Cancer.
    Huang Y; You M; Wu Q; Zhu W; Guo F; Lin W
    Ann Clin Lab Sci; 2022 Nov; 52(6):904-917. PubMed ID: 36564070
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CXCL11 Correlates with Immune Infiltration and Impacts Patient Immunotherapy Efficacy: A Pan-Cancer Analysis.
    Li Y; Han S; Wu B; Zhong C; Shi Y; Lv C; Fu L; Zhang Y; Lang Q; Liang Z; Yu Y; Tian Y
    Front Immunol; 2022; 13():951247. PubMed ID: 35935945
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FOXD1 is a prognostic biomarker and correlated with macrophages infiltration in head and neck squamous cell carcinoma.
    Liang H; Zhang C; Li C; Li C; Wang Y; Lin H
    Biosci Rep; 2021 Jul; 41(7):. PubMed ID: 34028536
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic and immunological role of Ras-related protein Rap1b in pan-cancer.
    Cui G; Wang C; Lin Z; Feng X; Wei M; Miao Z; Sun Z; Wei F
    Bioengineered; 2021 Dec; 12(1):4828-4840. PubMed ID: 34346294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multi-omics analysis of N6-methyladenosine reader IGF2BP3 as a promising biomarker in pan-cancer.
    Chen P; Xu J; Cui Z; Wu S; Xie T; Zhang X
    Front Immunol; 2023; 14():1071675. PubMed ID: 36761737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.